Eribulin efficacy in long responder patients with metastatic breast cancer: A multicentric observational study
This multicentric, retrospective study highlights eribulin as a potential second-line therapy for MBC with a median response duration of 25 weeks after 6 infusions. The safety and efficacy profiles align with previous studies, supporting its role as a viable treatment option. Notably, the response and PFS were independent of hepatic metastasis, suggesting benefit across various MBC subtypes, including those with liver involvement. However, the retrospective design warrants cautious interpretation, and further prospective studies are needed to confirm these findings and optimize eribulin's use, potentially through molecular profiling for personalized treatment strategies.
Authors
- J.P. Jacquin
- Laurys Boudin (ORCID: https://orcid.org/0000-0002-3641-1472)
- Nadine Dohollou (ORCID: https://orcid.org/0000-0003-2976-4090)
- Judith Passildas (ORCID: https://orcid.org/0000-0002-3575-7260)
- Catherine Abrial (ORCID: https://orcid.org/0000-0002-1759-9457)
- L. Uwer
- Véronique Lorgis
- Ioana Molnar (ORCID: https://orcid.org/0000-0001-5114-2648)
- Nawale Hajjaji (ORCID: https://orcid.org/0000-0002-8500-2309)
- Thierry Petit (ORCID: https://orcid.org/0000-0002-8746-0725)
- M Paillard
- M-A Mouret-Reynier
Institutions
- Inserm (FR)
- Centre Hospitalier Universitaire de Besançon (FR)
- Institut de Cancérologie de Lorraine (FR)
- Levi Strauss (United States) (US)
- Institute Cancer De La Loire Lucien Neuwirth (FR)
- Institut de Cancérologie de Bourgogne (FR)
- Polyclinique Bordeaux Nord Aquitaine (FR)
- Polyclinique de Bordeaux-Tondu (FR)
- Centre Jean Perrin (FR)
- Centre Oscar Lambret (FR)
- Hôpital d'Instruction des Armées Sainte-Anne (FR)
Publication Details
- Journal
- Cancer Epidemiology
- Published
- 2025-03-15
- DOI
- https://doi.org/10.1016/j.canep.2025.102800
- Primary Topic
- Cancer Treatment and Pharmacology
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Eisai